Chronic Obstructive Pulmonary Disease – Landscape & Forecast – Disease Landscape & Forecast
The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics will have a significant impact on this trend. Some generic LABA/ICS FDCs and LAMAs have already launched in the United States and Europe, and more will reach the market in the coming years. Although physicians will welcome additional treatment options for this chronic disease as a result of the development of novel drug classes, including biologics (e.g., IL-33, IL-13/IL-4, IL-5 inhibitors) and novel inhaled and nebulized therapies (e.g., PDE3/4 inhibitors), significant unmet need remains for therapies that can repair lung tissue or halt disease progression.
QUESTIONS ANSWERED
- Will LABA/LAMA FDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICS FDCs threaten these agents?
- What are key opinion leaders’ insights on current treatment options (e.g., GSK’s Advair, Trelegy, Breo; GSK / Innoviva’s Anoro; BI’s Spiriva, Stiolto / Spiolto; AstraZeneca’s Breztri, Symbicort)? What factors drive physicians’ treatment decisions?
- How will the market evolve over the next 10-year forecast period?
- Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted? Will the use of IL-5 inhibitors be accepted for COPD? How will the launch of these and other biologics influence the COPD market?
- What is the unmet need for COPD?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Chronic Obstructive Pulmonary Disease - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- Q4 2022
- December 2022
- November 2022
- October 2022
- Q3 2022
- August 2022
- July 2022
- Q2 2022
- June 2022
- May 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2021
- December 2021
- November 2021
- Q4 2022
- Market outlook
- Key findings
- Market share of COPD drug classes: 2021
- Market share of COPD drug classes: 2031
- COPD SWOT analysis
- Market drivers and constraints
- What factors are driving the market for chronic obstructive pulmonary disease?
- What factors are constraining the market for chronic obstructive pulmonary disease?
- Patient share of select drug classes for mild to moderate COPD in the G7: 2021-2031
- Patient share of select drug classes for severe to very severe COPD in the G7: 2021-2031
- Drug-class specific trends
- Brand and generic patient share of tiotropium in COPD: 2021-2031
- Major-market sales of LAMAs in COPD: 2021-2031
- Brand and generic sales of LABA/ICSs in COPD: 2021-2031
- U.S. patient share of LABA/ICS combinations in COPD: 2021-2031
- EU5 patient share of LABA/ICS combinations in COPD: 2021-2031
- Japan patient share of LABA/ICS combinations in COPD: 2021-2031
- Major-market sales and patient share of LABA/LAMA combinations for COPD: 2021-2031
- Major-market patient share of LABA/LAMA/ICS FDCs for mild to moderate COPD: 2021-2031
- Major-market patient share of LABA/LAMA/ICS FDCs for severe to very severe COPD: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions - COPD 2021-2031 - October 2022
- Brand and generic patient share of tiotropium in COPD: 2021-2031
- Major-market sales of LAMAs in COPD: 2021-2031
- Brand and generic sales of LABA/ICSs in COPD: 2021-2031
- U.S. patient share of LABA/ICS combinations in COPD: 2021-2031
- EU5 patient share of LABA/ICS combinations in COPD: 2021-2031
- Japan patient share of LABA/ICS combinations in COPD: 2021-2031
- Major-market sales and patient share of LABA/LAMA combinations for COPD: 2021-2031
- Major-market patient share of LABA/LAMA/ICS FDCs for mild to moderate COPD: 2021-2031
- Major-market patient share of LABA/LAMA/ICS FDCs for severe to very severe COPD: 2021-2031
- Market forecast dashboard - COPD 2021-2031 - October 2022
- Brand and generic patient share of tiotropium in COPD: 2021-2031
- Major-market sales of LAMAs in COPD: 2021-2031
- Brand and generic sales of LABA/ICSs in COPD: 2021-2031
- U.S. patient share of LABA/ICS combinations in COPD: 2021-2031
- EU5 patient share of LABA/ICS combinations in COPD: 2021-2031
- Japan patient share of LABA/ICS combinations in COPD: 2021-2031
- Major-market sales and patient share of LABA/LAMA combinations for COPD: 2021-2031
- Major-market patient share of LABA/LAMA/ICS FDCs for mild to moderate COPD: 2021-2031
- Major-market patient share of LABA/LAMA/ICS FDCs for severe to very severe COPD: 2021-2031
- Market forecast assumptions - COPD 2021-2031 - October 2022
- Etiology and pathophysiology
- Disease overview
- Etiology
- Causative factors for COPD
- Pathophysiology
- Mechanisms contributing to symptoms and progression of COPD
- Lung anatomy and pathogenic processes in COPD
- Inflammatory mechanisms of COPD
- Disease progression
- Key pathways and drug targets
- Potential biomarkers of COPD
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods
- Sources used for total prevalent cases of COPD
- Total prevalent cases of COPD : 2021-2031 (thousands)
- Disease definition
- Methods
- Sources used for diagnosed prevalent cases of COPD
- Diagnosed prevalent cases of COPD: 2021-2031 (thousands)
- Disease definition
- Methods
- Sources used for COPD segmented by severity
- Diagnosed prevalent cases of mild to moderate COPD: 2021-2031 (thousands)ttttttt
- Diagnosed prevalent cases of severe to very severe COPD: 2021-2031 (thousands)tttttttttt
- Number of drug-treated prevalent cases of mild to moderate COPD in the major pharmaceutical markets: 2020-2030 (thousands)
- Number of drug-treated prevalent cases of severe to very severe COPD in the major pharmaceutical markets: 2021-2031 (thousands)
- Disease definition
- Methods
- Sources used for acute exacerbations of COPD
- Acute exacerbations of COPD: 2021-2031
- Disease definition
- Methods
- Sources used for eosinophilic COPD
- Diagnosed prevalent cases of eosinophilic COPD: 2021-2031 (thousands)
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for COPD
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for COPD
- Current treatments used for COPD
- Market events impacting the use of key current therapies in COPD
- Advantages and disadvantages of tiotropium
- Advantages and disadvantages of aclidinium
- Advantages and disadvantages of glycopyrronium
- Advantages and disadvantages of nebulized glycopyrronium
- Advantages and disadvantages of revefenacin
- Advantages and disadvantages of umeclidinium
- Expert insight: LAMAs
- Advantages and disadvantages of indacaterol
- Advantages and disadvantages of olodaterol
- Expert insight: LABAs
- Advantages and disadvantages of indacaterol / glycopyrronium
- Advantages and disadvantages of vilanterol / umeclidinium
- Advantages and disadvantages of formoterol / aclidinium
- Advantages and disadvantages of olodaterol / tiotropium
- Advantages and disadvantages of formoterol / glycopyrronium
- Expert insight: LABA/LAMA FDCs
- Advantages and disadvantages of salmeterol / fluticasone propionate
- Advantages and disadvantages of formoterol / budesonide
- Advantages and disadvantages of vilanterol / fluticasone furoate
- Expert insight: LABA/ICS FDCs
- Advantages and disadvantages of formoterol / glycopyrronium / beclomethasone
- Advantages and disadvantages of vilanterol / umeclidinium / fluticasone furoate
- Advantages and disadvantages of formoterol / glycopyrronium / budesonide
- Expert insight: LABA/LAMA/ICS FDCs
- Advantages and disadvantages of roflumilast
- Expert insight: roflumilast
- Advantages and disadvantages of short-acting bronchodilators
- Expert insight: short-acting bronchodilators
- Advantages and disadvantages of methylxanthines
- Expert insight: methylxanthines
- Medical practice
- Overview
- Factors influencing drug selection in COPD
- Inhaler devices for COPD
- Treatment decision tree for COPD: United States
- Treatment decision tree for COPD: Europe
- Treatment decision tree for COPD: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in chronic obstructive pulmonary disease
- Top unmet needs in chronic obstructive pulmonary disease: current attainment and future attainment
- Expert insight: unmet needs in chronic obstructive pulmonary disease
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for COPD
- Estimated launch dates of key emerging therapies for the treatment of COPD
- Dupilumab profile
- Analysis of the clinical development program for dupilumab
- Expert insight: dupilumab
- Expectations for launch and sales opportunity of dupilumab in COPD
- Benralizumab profile
- Analysis of the clinical development program for benralizumab
- Expert insight: benralizumab
- Expectations for launch and sales opportunity of benralizumab in COPD
- Mepolizumab profile
- Analysis of the clinical development program for mepolizumab
- Expert insight: mepolizumab
- Expectations for launch and sales opportunity of mepolizumab in COPD
- Ensifentrine profile
- Analysis of the clinical development program for ensifentrine
- Expert insight: ensifentrine
- Expectations for launch and sales opportunity of ensifentrine in COPD
- Itepekimab profile
- Analysis of the clinical development program for itepekimab
- Expectations for launch and sales opportunity of itepekimab in COPD
- Tozorakimab profile
- Analysis of the clinical development program for tozorakimab
- Expectations for launch and sales opportunity of tozorakimab in COPD
- Expert insight: IL-33 inhibitors
- Early-phase pipeline analysis
- Select compounds in early-phase development for COPD
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in COPD: United States
- General reimbursement environment: United States
- Key market access considerations in COPD: EU5
- General reimbursement environment: EU5
- Key market access considerations in COPD: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- COPD bibliography
- Key findings
Anupama Joshi, M.S. (Pharm.), Healthcare Research & Data Analyst, Immune and Inflammation. Anupama is an analyst on the Immune and Inflammation team at Clarivate. Her focus is on respiratory diseases, particularly chronic obstructive pulmonary disease. Prior to joining Clarivate, Ms. Joshi was a research scientist in Dr. Reddy’s Laboratories. She obtained her master’s degree in pharmaceutical analysis from the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), India.
Navya Vardhan, M.Sc., Epidemiologist, Epidemiology. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.